1 Introduction Cancer persists as the second leading cause of global mortality, with epidemiological projections estimating 19.97 million new cases and 9.74 million deaths in 2024 ( Nutraceuticals have emerged as compelling candidates in translational oncology, leveraging their dual capacity to potentiate anticancer effects while mitigating treatment-related toxicity ( 2 O 2 )-mediated responses, including adenosine triphosphate (ATP) depletion, iron-regulated epigenetic reprogramming, anti-apoptotic protein B cell lymphoma 2 (Bcl-2) inhibition, Bax (Bcl-2 associated X protein, a well-known pro-apoptotic mediator) activation, mitochondrial hyperpolarization induction, the cleavage of poly (ADP-ribose) polymerase (PARP, a known apoptotic indicator) and caspases, mainly caspases 3 and 7 as well as targeting hypoxia-inducible factor-1 ( HIF- ) ( The therapeutic application of VC in oncology has been plagued by persistent controversies, particularly regarding dose-response relationships and administration route efficacy

GIVEAWAYS INCREMENT SERVICES Single-component Reagents of Assay Kit Lysis Buffer Specific for ELISA / CLIA Quality Control of Kit ELISA Kit Customized Service Disease Model Customized Service Serums Customized Service TGFB1 Activation Reagent Real Time PCR Experimental Service Streptavidin Fast blue Protein Stain solution Single-component Reagents of FLIA Kit Streptavidin-Agarose Beads
In this section, we systematically review disease-specific microbiome alterations, with a focus on Alzheimers, Parkinsons, and related disorders
Mov Disord 24:979983 Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM (2017) Phase IIb study of intranasal glutathione in Parkinson's disease
Achieve a smoother, softer complexion with every use